Primary treatment of Hodgkin s disease
|
|
- Arthur Hancock
- 5 years ago
- Views:
Transcription
1 DOI: /annonc/mdf653 Primary treatment of Hodgkin s disease G. P. Canellos Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA Introduction Therapeutic research in human tumors has followed the lead from the early trials of combination chemotherapy for the treatment of advanced Hodgkin s disease (HD). The 1960s saw the introduction of new drugs and radiation equipment that were useful in the treatment of lymphoma in general. Chemotherapy given as single agents in moderate doses to patients previously treated with steroids and radiation therapy was the standard of the day. After anti-tumor activity was established, it remained to use them in combination in previously untreated patients with measurable, advanced disease. The precedent was already being set in the treatment of childhood acute lymphoblastic leukemia with encouraging preliminary results. The National Cancer Institute s (NCI) Medicine Branch group pioneered the effective use of combined chemotherapy in the form of combination chemotherapy composed of nitrogen mustard, vincristine, procarbazine and prednisone (known as MOPP). This regimen could achieve a high order of response with prolonged duration of complete remission that continued indefinitely in a significant number of patients [1, 2]. Table 1 is an outline of alkylating agent-containing regimens commonly used in the treatment of HD [3, 4]. These other variant regimens also confirmed their effectiveness in clinical trials. Initial trials demonstrated that MOPP could not only cure previously untreated patients but also patients in relapse from radiation therapy [5]. Maintenance therapy with intermittent MOPP beyond 6 8 monthly courses of MOPP did not increase the cure rate. There was some suggestion that the regimen was possibly as effective as radiation alone in localized disease [6]. The long-term toxicity of alkylating agents contained in combined MOPP-like regimens primarily affected bone marrow stem cells resulting in myelodysplasia leukemia and germ cells resulting in sterilization thus prompting a search for less toxic but equally effective treatments [7 9]. The combination of doxorubicin, vinblastine, bleomycin and dacarbazine (ABVD) was introduced by the NCI Milan group and proved an effective substitute which led to its acceptance as the current standard in the USA. Many of the newer and more intensive regimens are currently being compared with ABVD. A variety of active non-alkylating agent-containing regimens are shown in Table 2. They exist in phase II trials but have not been compared with one another in phase II trials [10 12]. In recent years, regimens have been changed to include the following: alternating combinations of active drugs; hybridized regimens; dose intensification per se and addition of other agents. Hybridized or alternating regimens showed some superiority to MOPP (or variant) alone in response and progression-free survival [13 15]. The move to replace or decrease the amount of radiation therapy given to young patients in order to reduce long-term radiation-induced secondary malignancies has given momentum to the use of chemotherapy alone in earlier stages. The ABVD regimen provided the means to do so with its relative safety as a systemic treatment. Many prospective trials have shown a superiority in relapse-free survival for combined modality over radiation therapy alone, although overall survival was not necessarily improved. Combined modality therapy for localized disease in recent series can be expected to generate a 5-year freedom from progression of 85% with an overall survival in the range of >80% [16, 17]. The inclusion of chemo- Table 1. Alkylating agent-containing regimens active in the treatment of Hodgkin s disease Regimen [reference] Dose (mg/m 2 ) Days MOPP [2] Mechlorethamine 6 1, 8 Vincristine 1.4 1, 8 Procarbazine Prednisone MVPP [3] Mechlorethamine 6 1, 8 Vinblastine 100 1, 8 Procarbazine Prednisone ChlVPP [4] Chlorambucil 6 (total) p.o Vinblastine 6 (max. 10) 1, 8 Procarbazine Prednisone European Society for Medical Oncology
2 154 Table 2. Non-alkylating combination chemotherapy regimens Regimen [reference] Dose (mg/m 2 ) Days ABVD [10] Doxorubicin 25 i.v. 1, 15 Bleomycin 10 units 1, 15 Vinblastine 6 1, 15 Dacarbazine 375 1, 15 EVA [11] Etoposide 100 1, 2, 3 Vinblastine 6 1 Doxorubicin 50 1 q. 28 days NOVP [12] Mitoxantrone 10 1 Vincristine q. 21 days Vinblastine 6 1 Prednisone therapy in the combined modality approach and improved radiographic staging for localized disease has obviated the need for staging laparotomy. These include the use of and radionuclide scanning with 67 gallium and positron emission tomography with 18 F-fluoro-deoxyglucose to evaluate the status of residual masses. Nodular lymphocyte predominant HD represents a unique variant of the disease and a different philosophy of management. It has the immunophenotypic and genetic features of a low-grade B-cell lymphoma, often presenting as localized disease. Radiation therapy alone is usually sufficient to control or cure the disease [18]. Alkylating agent-containing regimens may be more effective for advanced stages of this unique group which represents only 5% of patients. The treatment of advanced disease is not optimal and requires improvement since there is a 30 40% likelihood of relapse following 6 8 cycles of any of the standard regimens. The challenge to improve therapeutic results has to be balanced by the risk of increased drug-induced toxicity that results from agents, such as etoposide or alkylating agents, when used in higher doses. Dose intensity is relevant since escalated or intensive dose regimens tend to have a higher response rate, but whether a real survival advantage ensues remains uncertain. Further, escalated doses used with autologous peripheral stem cell or bone marrow transplantation can cure patients who relapse from conventional dose therapy, which further suggests a dose response effect in Hodgkin s disease. Management of localized disease Several long-term follow-up series of laparotomy-staged patients treated with extensive radiation alone have demonstrated a 10-year relapse-free survival of 76 83% for stages I or I/II in three series of 699 patients. The late toxicity of ischemic heart disease (16%) and second tumors (10%) was noted in long-term follow-up. The radiation fields usually included the mantle field of the mediastinum/neck/axillae and extension to the upper para-aortic nodes. The average dose was 35 Gy with a boost to the involved field up to 44 Gy. The dose to uninvolved nodal sites need not exceed 30 Gy. In general, the rate of clinical hypothyroidism is 14%. The in-field disease control rate exceeded 95% [19 21]. Using the European Organization for Research and Treatment of Cancer (EORTC) favorable criteria, young women <26 years of age presenting with clinical stage I asymptomatic disease, and especially patients with lymphocyte predominant nodular or nodular sclerosis histology, can be treated with radiation alone to a mantle field without a laparotomy with excellent outcomes; however, the issue of the risk of irradiationinduced breast cancer would be expected to be highest in young females. The long-term progression-free rate approaches 80% for this subgroup [22]. Mantle-only radiation therapy in localized classical HD staged without laparotomy has only a 58% 10-year progression-free survival [23]. In classical HD, laparotomy staging selected patients for mantle only radiation resulted in a 76% disease-free rate at 10 years [24]. The major concern now is the potential for an increasing radiationinduced complication rate with even longer follow-up. The clinical criteria which define the risk for subsequent dissemination or relapse in patients with unfavorable localized presentations have been presented by the EORTC (Table 3). Bulky mediastinal presentations (mass of >10 cm or >33% of the thoracic diameter) have been shown to have at least a 50% chance of recurrence when radiation therapy alone has been used [25]. This has been reduced considerably to 20% or less when systemic therapy is followed by localized irradiation [26]. Unfavorable features also include B symptoms and an ESR >30 mm, no symptoms but an ESR >50 mm, and >2 nodal areas. A series of randomized trials have shown a consistent superiority of combined modality therapy over extensive nodal irradiation alone in relapse-free survival [16, 17]. The issue of the elimination of radiation therapy in patients with Table 3. Unfavorable risk factors in localized disease (EORTC) a Mediastinal mass ( 33% thoracic diameter) Age >50 years Elevated erythrocyte sedimentation rate (ESR) a Ιnvolved sites 4 with the same side of diaphragm Mixed cellularity histology a Unfavorable entails ESR 50 or 30 with B symptoms. Any one of these factors in clinical stage I/II is unfavorable (Carde et al. [25]). EORTC, European Organisation for Research and Treatment of Cancer.
3 155 early stages but without bulk disease has been raised based on the preliminary observations. ABVD alone has been shown to have a low relapse rate when given to such patients in a single pilot trial [27]. The EORTC and NCI (Canada) are addressing this question in prospective trials. A relatively modest randomized trial in stage I, II patients without bulk of disease comparing ABVD alone versus the same ABVD regimen but with mantle or involved field radiation showed an equivalent result at 3 years of follow-up [28]. Since the long-term risk of second neoplasms exceeds 20 25% at years based on the techniques/doses of radiation used in the past, systemic therapy alone or that combined with very localized (limited) irradiation is being considered for most patients with nonbulky localized disease. What is unknown is whether these reduced radiation fields will have a commensurate reduction in second radiation-induced cancers. The latter include inthe-field sarcoma, epithelial aerodigestive cancers and breast cancer [29 31]. There is no uniform standard, but four cycles of ABVD plus involved field irradiation of at least 30 Gy to the involved field is commonly used for patients presenting with favorable prognosis localized HD. Treatment of recurrence from localized disease Localized disease treated with radiation alone will have a recurrence rate which varies from 20% to 30% for patients without negative prognostic features and carefully staged by laparotomy to >40% for clinically staged patients with either bulky mediastinal masses, elevated sedimentation rate, multiple nodal area involvement or extranodal extension. The majority of relapses will be detected in extranodal or nodal sites not previously irradiated and usually occur within the first 3 years following initiation of irradiation. Late relapses are rare with 5% at 4 years and 3.4% at 5 years in two series [32, 33]. Patients relapsing from primary radiation therapy can achieve an excellent response to combination chemotherapy. Patients who were originally in pathologic stage I/IIA can expect a chemotherapy-induced complete response (CR) rate of 80 90% with a 60 70% 10-year survival [34]. Disseminated recurrence following radiation alone has a second CR rate of 70% with a 58% 10-year survival [35]. The current use of combined modality, especially if a full six cycles of chemotherapy is given, has reduced the relapse rate, but the potential for drug resistance is still a factor. Second-line therapy is needed similar to patients who relapsed after chemotherapy alone for stage III or IV disease if patients had received combined modality therapy as primary treatment. Treatment of advanced disease The vast majority of patients presenting in stage III or IV are treated with combination chemotherapy. Over the passage of time, the regimens have varied in both their composition and Table 4. Prognostic factors which predict relapse of advanced disease a Stage IV Serum albumin <4 g Male gender Hemoglobin <10 g Age 45 years WBC >15 000/mm 3 Absolute lymphocyte count <600/mm 3 No. of factors (% of patients) Relapse-free survival at 6 years (%) None (7) 85 1 (22) (29) (23) (12) (7) a Treated with systemic therapy alone or combined with irradiation (adapted from Hasenclever and Diehl [38]). the schedules of drugs used and, in addition, some regimens have been used with radiation therapy. At the time of writing, the general standard in the USA and many centers in Europe, outside of a clinical trial, is ABVD for six to eight cycles. The Cancer and Leukemia Group B has conducted two trials where ABVD has been prospectively compared (see below) with MOPP alone; 12 months of MOPP alternating with ABVD; and MOPP/ABV hybrid [36, 37]. Long-term follow-up of these trials have shown that ABVD was equivalent or superior in progression-free survival without the toxicity of alkylating agents namely, more profound myelosuppression, sterility and leukemogenesis. However, the overall survival showed no difference due to the ability of second-line therapy to salvage relapsed patients. In general, combination chemotherapy, including ABVD, used for stage III/IV disease should achieve a clinical CR rate in the 70 80% range with an approximately 20 30% relapse rate over time. The outcome is directly influenced by the number of negative prognostic factors (Table 4) [38]. The majority of patients present with two to three of these negative factors. When five or more are present, there is an overall 5-year survival that is somewhat <50%. These poor risk patients represent only 7% of cases. In addition to clinical prognostic factors in advanced disease, there may be biological factors that correlate with response to chemotherapy. They include presence of Epstein Barr viral latent antigen (LMP-1) positivity exerting a favorable outcome [39]. The presence of tissue eosinophilia and elevated serum IL-10 levels have been associated with an inferior failure-free survival [40, 41]. With a salvage rate of 30 50%, an overall survival at 5 years could be in the range of 80%. The potential cure rate is in the range of 70%. With conventional dose chemotherapy regimens,
4 156 the overall survival outcome is likely to be similar regardless of regimen. The major differences in the follow-up will be in the toxicity. Although the standard is ABVD, there is certainly a need for newer regimens that might offer the potential for an improved outcome. The German Hodgkin s Lymphoma Study Group (GHSG) pioneered the development of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone), a regimen based on a model which proposed to increase the failure-free survival by 10 20% by modest dose intensification. They also tested an escalated version given every 21 days which increased the doxorubicin 20% (from 25 to 30 mg/m 2 ); cyclophosphamide 90% (from 650 to 1200 mg/m 2 ) and etoposide 100% (from 100 to 200 mg/m 2 ) and required growth factor support. It was compared with regular dose BEACOPP and cyclophosphamide, vincristine, procarbazine and prednisone (COPP)/ABVD as the standard in a prospective randomized trial. With a median follow-up of 56 months, the freedom from treatment failure rate was 87%, 76% and 69%, respectively. The overall survival at five years was 91%, 88% and 83%, respectively [42]. The escalated BEACOPP was significantly superior in overall survival to COPP/ABVD but not the standard BEACOPP. The escalated BEACOPP was also associated with greater hematological toxicity. Nine leukemias out of 466 patients were noted in the escalated group compared with 4 of 469 with standard BEACOPP and 1 of 260 in COPP/ABVD. The BEACOPP regimen (standard dose) is now being compared with ABVD in a prospective randomized trial. Stanford V is a combined modality program which entails 3 months of weekly chemotherapy and steroids followed by irradiation (36 44 Gy) to initial bulky and residual radiographic sites. The most recent analysis in 142 patients demonstrated an 89% freedom from progression at a median of 5.4 years with an overall survival of 96%. These excellent results need confirmation but it should be noted that 32% of patients had bulky (>33% intrathoracic diameter) stage I or II. There were no treatment deaths or apparent sterilization. The vast majority (91%) in the series received radiation therapy [43]. The Milan NCI group piloted VEBEP (etoposide, epirubicin, bleomycin, cyclophosphamide, and prednisolone), a regimen given for eight cycles and followed with complementary radiotherapy to sites of prior disease. The complete remission rate was high (94%) with 78% freedom from progression at 6 years [44]. These excellent results were associated with gonadal damage, although this was reversible in half of the men. This again illustrates the toxic risks associated with more intensified treatment. It is possible that a relatively small fraction of patients (10 20%) will be spared the necessity of salvage therapy when higher dose alkylating agents or etoposidecontaining regimens are used compared with ABVD or ABVD-like regimens (with or without radiotherapy). This means that 60 70% of patients are exposed to the potential of a variety of unnecessary toxic risks. If salvage therapy is effective in that 10 20% group as opposed to de novo refractory or induction failures, then the group of patients treated with the less toxic regimen could show an equivalent survival with less overall toxicity. This emphasizes the importance of prognostic factors. However, it still remains to be seen whether more cytotoxic regimens will prove superior to ABVD in overall disease-related survival in patients with clinical factors predicting a poorer overall survival. Many trials including BEACOPP and VEBEP trials have been combined with radiation and do not permit an assessment of the impact of chemotherapy alone. A recent EORTC trial tested the value of complementary involved field radiotherapy in stage III/IV patients in CR after completing 6 8 cycles of MOPP/ABV in a randomized trial. After 6 years of follow-up, the relapse-free and overall survival for the radiation group was 85% versus 82%, 82% versus 88% for the radiated and non-irradiated groups, respectively [45]. All partial remissions received irradiation with an outcome similar to CR patients. Radionuclide scans to determine the status of residual mass in partial remission patients were not performed. It is conceivable that some of the PR patients may have been in a pathological CR as well. The major toxicity of the ABVD regimen is myelosuppression, but hair loss is common. Sterility is uncommon, but sperm banking can be recommended as an extra precaution. The pulmonary toxicity of bleomycin alone or with radiation therapy is usually mild but is a toxic consideration and monitoring of clinical symptoms as well as periodic carbon monoxide diffusion (DLCO) in selected patients may be warranted. There is often a transient decrease in pulmonary function. Similarly, cardiac dysfunction in the absence of prior left ventricular irradiation is unusual [46, 47]. Six cycles of the ABVD regimen contains doxorubicin 300 mg/m 2 which is below the known total dose that has the potential for cardiac toxicity. Myelosuppression is reversible in almost all cases and prolonged myeloid stem cell compromise or myelodysplasia is very rare. References 1. DeVita VT Jr, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: DeVita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin s disease. Ann Intern Med 1970; 73: Sutcliffe SB, Wrigley PFM, Peto J et al. MVPP chemotherapy regimen for advanced Hodgkin s disease. Br Med J 1978; 1: Selby P, Patel P, Milan S et al. ChlVPP combination chemotherapy for Hodgkin s disease: long term results. Br J Cancer 1990; 62: Canellos GP, Young TC, DeVita VT Jr. Combination chemotherapy for advanced Hodgkin s disease in relapse following extensive radiotherapy. Clin Pharm Ther 1972; 13:
5 Young RC, Canellos GP, Chabner BA et al. Maintenance chemotherapy for advanced Hodgkin s disease in remission. Lancet 1973; 1: Canellos GP, DeVita VT, Arseneau JC et al. Second malignancies complicating Hodgkin s disease in remission. Lancet 1975; 1: Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 1980; 93: Kaldor JM, Day NE, Clarke A et al. Leukemia following Hodgkin s disease. N Engl J Med 1990; 322: Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin s disease. Cancer Treat Rev 1982; 9: Canellos GP, Petroni GR, Barcos M et al. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin s disease in relapse following MOPP. J Clin Oncol 1995; 13: Hagemeister FB, Cabanillas F, Velasquez WS et al. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin s disease. Semin Oncol 1990; 17 (Suppl. 10): Bonadonna G, Valagussa P, Santoro A. Alternating non-crossresistant combination chemotherapy or MOPP in stage IV Hodgkin s disease: a report of 8-year results. Ann Intern Med 1986; 104: Radford JA, Crowther D, Rohatiner AZS et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin s disease. J Clin Oncol 1995; 13: Hancock BWS, Vaughan-Hudson G, Vaughan-Hudson B et al. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin s disease: results of a British National Lymphoma Investigation Trial. J Clin Oncol 1992; 10: Cosset JM, Fermé C, Noordijk EM et al. Combined modality treatment for poor prognosis stages I and II Hodgkin s disease. Semin Radiat Oncol 1996; 6: Specht L, Gray RG, Clarke MJ et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin s disease: a meta-analysis of 23 randomized trials involving 3888 patients. J Clin Oncol 1998; 16: Bodis S, Kraus MD, Pinkus G et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin s disease. J Clin Oncol 1997; 15: Vlachaki MT, Ha CS, Hagemeister FB et al. Long-term outcome of treatment for Ann Arbor stage I Hodgkin s disease: patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Phys 1997; 39: Sears JD, Greven KM, Ferree CR, D Agostino RB Jr. Definitive irradiation in the treatment of Hodgkin s disease. Analysis of outcome, prognostic factors, and long-term complications. Cancer 1997; 79: Dühmke E, Franklin J, Pfreundschuh M et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early stage Hodgkin s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001; 19: Cosset JM, Henry-Amar M, Meerwaldt JH et al. The EORTC trials for limited stage Hodgkin s disease. Eur J Cancer 1992; 28A: Wirth A, Chao M, Corry J et al. Mantle irradiation alone for clinical stage I II Hodgkin s disease: long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 1999; 17: Jones E, Mauch P. Limited radiation therapy for selected patients with pathological stages IA and IIA Hodgkin s disease. Semin Radiat Oncol 1996; 6: Carde P, Hagenbeek A, Hayat M et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin s disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11: Colonna P, Jais J-P, Desablens B et al. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin s disease treated by ABVD plus radiotherapy: 10-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol 1996; 14: Rueda A, Alba E, Ribelles N et al. Six cycles of ABVD in the treatment of stage I and II Hodgkin s disease: a pilot study. J Clin Oncol 1997; 15: Straus DJ, Yahalom J, Zelenetz A et al. Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone versus ABVD plus radiation therapy for early stage non bulky Hodgkin s disease. Blood 2001; 98: 769a. 29. Bhatia S, Robison LL, Oberlin O et al. Breast cancer and other second neoplasms after childhood Hodgkin s disease. N Engl J Med 1996; 334: van Leeuwen FE, Klokman WJ, Hagenbeek A et al. Second cancer risk following Hodgkin s disease: a 20-year follow-up study. J Clin Oncol 1994; 12: Sankila R, Garwicz S, Olsen JH et al. Risk of subsequent malignant neoplasms among 1641 Hodgkin s disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. J Clin Oncol 1996; 14: Bodis S, Henry-Amar M, Bosq J et al. Late relapse in early-stage Hodgkin s disease patients enrolled on European Organization for Research and Treatment of Cancer protocols. J Clin Oncol 1993; 11: Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin s disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 1997; 33: Brierley JD, Rathmell AJ, Gospodarowicz MK et al. Late relapse after treatment for clinical stage I and II Hodgkin s disease. Cancer 1997; 79: Hoppe RT. The management of Hodgkin s disease in relapse after primary radiation therapy. Eur J Cancer 1992; 28A: Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin s disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 1992; 327: Duggan D, Petroni G, Johnson J et al. MOPP/ABV versus ABVD for advanced Hodgkin s disease: a preliminary report of CALGB 8952 (with SWSOG, ECOG, NCIC). Proc Am Soc Clin Oncol 1997; 16: 12a. 38. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin s disease. N Engl J Med 1998; 339: Murray PG, Billingham LJ, Hassan HT et al. Effect of Epstein Barr virus infection on response to chemotherapy and survival in Hodgkin s disease. Blood 1999; 94: Sarris AH, Kliche KO, Pethambaram P et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin s disease and are
6 158 associated with inferior failure-free survival. Ann Oncol 1999; 10: von Wasielewski R, Seth S, Franklin J et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin s disease, allowing for known prognostic factors. Blood 2000; 95: Diehl V, Franklin J, Paulus U et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin s disease: final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood 2001; 98: 769a. 43. Horning SJ, Hoppe RT, Breslin S et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin s disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: Viviani S, Bonfante V, Santoro A et al. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin s disease. Cancer J Sci Am 1999; 5: Raemaekers JMM, Aleman B, Henry-Amar M et al. Involved field irradiation (IFRT) does not improve outcome in patients with stage III/IV Hodgkin s lymphoma (HL) in complete remission after MOPP/ABV (M/A): Results of the randomised EORTC trial Blood 2001; 98: 768a. 46. Horning SJ, Adhikari A, Rizk N et al. Effect of treatment for Hodgkin s disease on pulmonary function: result of a prospective study. J Clin Oncol 1994; 12: Valagussa P, Santoro A, Bonadonna G. Thyroid, pulmonary, and cardiac sequelae after treatment for Hodgkin s disease. Ann Oncol 1992; 3 (Suppl. 4): S111 S115.
Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment
HODGKIN LYMPHOMA: CLINICAL CHALLENGES Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment John Radford 1 1 Professor of Medical Oncology, Christie Hospital and The University of
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationRadiation therapy has a dramatic effect on lymphomas, and has played an important role in treating Hodgkin
COUNTERPOINTS Current Controversies in Hematology and Oncology Can Radiotherapy Be Omitted in Patients With Localized Hodgkin Lymphoma? Radiation therapy has a dramatic effect on lymphomas, and has played
More informationEvolving Approaches to Primary Treatment of Hodgkin Lymphoma
Evolving Approaches to Primary Treatment of Hodgkin Lymphoma Joseph M. Connors Two challenges confront the clinician treating Hodgkin lymphoma today: achieving a high level of effectiveness while minimizing
More informationTHE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982)
EORTC Lymphoma Group THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982) J. Thomas, C. Fermé, E.M. Noordijk, H. Eghbali and M. Henry-Amar 7th International
More informationComparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):
Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial H. Eghbali, P.
More informationPrinted by Martina Huckova on 10/3/2011 3:04:43 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive
NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform NCCN consensus. Category 2A: The recommendation
More informationSerum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma
Original article Annals of Oncology 13: 1908 1914, 2002 DOI: 10.1093/annonc/mdf333 Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationOriginal Articles. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin s disease
RUPALI et al. : AETIOLOGY OF PROLONGED FEVER IN HIV-INFECTED ADULTS Original Articles 189 Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for
More informationLong-term risk of second malignancy after treatment of Hodgkin s disease: the influence of treatment, age and follow-up time
Original article Annals of Oncology 13: 1786 1791, 2002 DOI: 10.1093/annonc/mdf289 Long-term risk of second malignancy after treatment of Hodgkin s disease: the influence of treatment, age and follow-up
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer
More informationEnd-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin s lymphoma
original article Annals of Oncology 22: 910 915, 2011 doi:10.1093/annonc/mdq549 Published online 15 October 2010 original article End-of-treatment but not interim PET scan predicts outcome in nonbulky
More information2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA
2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until
More informationHODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)
HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationTreatment of Forty Adult Patients with Hodgkin Disease; Baghdad Teaching Hospital Experience
Original Article Treatment of Forty Adult Patients with Hodgkin Disease; Baghdad Teaching * Alaadin S. Naji* Ahmed A. AL - Saffar* Mazin A. Shubbar* Bassam F. Matti* Adil Siwan* Ammar F. Majeed* Ali M.Jawad*
More informationRECENT APPROACHES IN THE TREATMENT OF HODGKIN S LYMPHOMA. Luděk Raida
Volume 142, 1999 13 RECENT APPROACHES IN THE TREATMENT OF HODGKIN S LYMPHOMA Luděk Raida Haemato-oncology Department of University Hospital, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic Received August
More informationRadiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2
Radiation and Hodgkin s Disease: A Changing Field Sravana Chennupati Radiation Oncology PGY-2 History of Present Illness 19 yo previously healthy male college student began having pain in his R shoulder
More informationIAEA Pediatric Radiation Oncology Training Dr Laskar Version 1 June 2009 RADIATION THERAPY FOR PEDIATRIC HODGKIN S DISEASE
RADIATION THERAPY FOR PEDIATRIC HODGKIN S DISEASE THOMAS HODGKIN 1832 On Some Morbid Appearances of the Absorbent Glands & Spleen GLOBAL INCIDENCE Region Cases per 100,000 children United States 0.5 European
More informationPractical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
More informationFirst Line Management of Classical Hodgkin Lymphoma
First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /
More informationHodgkin Lymphoma Status of the art of treatment
11.05.2016 1 Hodgkin Lymphoma Status of the art of treatment Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Question No 1: Which statement regarding 1 st line treatment of early
More informationPrinciples of Chemotherapy in Hodgkin Lymphoma
Principles of Chemotherapy in Hodgkin Lymphoma 9 Patrice Carde and Peter Johnson Contents 9.1 Historical Introduction... 141 9.2 Chemotherapy Applied to Advanced Stage HL: Theories and Practice... 142
More informationFor more than a century after Thomas Hodgkin first described
The new england journal of medicine review article Current Concepts Early-Stage Hodgkin s Lymphoma James O. Armitage, M.D. For more than a century after Thomas Hodgkin first described the disease that
More informationXVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma
Hematological Oncology Hematol Oncol 2015; 33: 90 95 Published online in Wiley Online Library (wileyonlinelibrary.com).2226 Supplement Article XVIII. Management of nodular lymphocyte predominant Hodgkin
More informationTreatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research
Treatment of Early Stage Hodgkin Lymphoma Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Conflict of Interest Disclosure I hereby declare the following
More informationStaging Laparotomy in the Management of Hodgkin s Disease: Is it Still Necessary?
Staging Laparotomy in the Management of Hodgkin s Disease: Is it Still Necessary? PRATIK S. MULTANI, MICHAEL L. GROSSBARD Department of Medicine and Hematology/Oncology Unit, Massachusetts General Hospital,
More informationNIH Public Access Author Manuscript Expert Opin Pharmacother. Author manuscript; available in PMC 2011 December 1.
NIH Public Access Author Manuscript Published in final edited form as: Expert Opin Pharmacother. 2010 December ; 11(17): 2891 2906. doi:10.1517/14656566.2010.515979. Hodgkin s Lymphoma Therapy: Past, Present,
More informationROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY
ROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY EPIDEMIOLOGY HODGKIN LYMPHOMA - INCIDENCE EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY BY AGE NUMBER OF PEOPLE
More informationHodgkin Lymphoma-Unfavorable Clinical Stage I and II EVIDENCE TABLE
. Kaplan HS. Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res. 966;6(6):-4.. Rosenberg SA, Kaplan HS. Evidence for an orderly progression in the spread of Hodgkin's
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationAdvanced stage HL The old and new match: BEACOPP
27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment
More informationThe involved field is back: issues in delineating the radiation field in Hodgkin s disease
Symposium article Annals of Oncology 13 (Supplement 1): 79 83, 2002 DOI: 10.1093/annonc/mdf616 The involved field is back: issues in delineating the radiation field in Hodgkin s disease J. Yahalom 1 *
More informationNodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management
HODGKIN LYMPHOMA: NEW INSIGHTS AND NEW APPROACHES Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management Dennis A. Eichenauer 1,2 and Andreas Engert 1,2 1 First Department
More informationLymphomas and multiple myeloma 12/23/2018 1
60 Lymphomas and multiple myeloma 12/23/2018 1 Lymphomas Lymphoma is cancer of the lymphatic system. Lymphomas are subdivided into two main categories: Hodgkin's lymphoma (HL) and non- Hodgkin's lymphoma
More informationTrial Design. Journal of Clinical Oncology, Vol 10, No 8 (August), 1992: pp
Alternating With EVAP Is Superior to Alone in the Initial Treatment of Advanced Hodgkin's Disease: Results of a British National Lymphoma Investigation Trial By B.W. Hancock, G. Vaughan Hudson, B. Vaughan
More informationRadiotherapy Alone Versus Combined-Modality Therapy for Initial Treatment of Early Stage Hodgkin's Lymphoma
Radiotherapy Alone Versus Combined-Modality Therapy for Initial Treatment of Early Stage Hodgkin's Lymphoma Hanan Shawky Gamal El-Deen * and Amr Abd- El Aziz Ghannam Clinical Oncology Department, Tanta
More informationLymphocyte-Depleted Classical Hodgkin s Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
Published Ahead of Print on September 12, 211 as 1.12/JCO.211.36.473 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.211.36.473 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R
More informationHodgkin s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Hodgkin s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease Volker Diehl, Harald Stein, Michael Hummel, Raphael Zollinger, and Joseph M. Connors Hodgkin s lymphomas
More informationOne, the UK RAPID trial, including patients with early stage disease stage 1 and 2A nonbulky.
Martin Hutchings, MD, PhD Department of Hematology The Finsen Centre, National Hospital Copenhagen University Hospital Copenhagen, Denmark Welcome to Managing Hodgkin Lymphoma. My name is Martin Hutchings.
More informationRisk, Cure and Complications in Advanced Hodgkin Disease
Risk, Cure and Complications in Advanced Hodgkin Disease Sandra J. Horning Stanford University, Stanford, CA Current therapy for Hodgkin disease is aimed at high cure rates and optimal survivorship. Although
More informationoriginal article introduction original article
Annals of Oncology 19: 763 768, 2008 doi:10.1093/annonc/mdm575 Published online 6 January 2008 ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin s lymphoma: results
More informationRESEARCH ARTICLE. Effects of Radiotherapy on the Risk of Developing Secondary Malignant Neoplasms in Hodgkin s Lymphoma Survivors
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.2.749 Effects of Radiotherapy on Risk of Developing Secondary Malignant Neoplasms in Hodgkin s Lymphoma Survivors RESEARCH ARTICLE Effects of Radiotherapy on
More informationCitation for published version (APA): Aleman, B. M. P. (2007). Optimizing treatment of patients with Hodgkin's lymphoma
UvA-DARE (Digital Academic Repository) Optimizing treatment of patients with Hodgkin's lymphoma Aleman, B.M.P. Link to publication Citation for published version (APA): Aleman, B. M. P. (2007). Optimizing
More informationFirst line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early versus Advanced Stage Disease Presented
[Editor s note: Dr. Even's video transcript has been edited to improve readability] you today about the management of Hodgkin lymphoma in 2016. Welcome to Managing Hodgkin Lymphoma. My name is Andy Evens,
More informationSUPRADIAPHRAGMATIC EARLY STAGE HODGKIN'S DISEASE: DOES MANTLE RADIATION THERAPY STILL HAVE A ROLE?
decision making and problem solving Haematologica 1996; 81:138-142 SUPRADIAPHRAGMATIC EARLY STAGE HODGKIN'S DISEASE: DOES MANTLE RADIATION THERAPY STILL HAVE A ROLE? Giovanni Frezza, Enza Barbieri, Pier
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 21 JULY 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage
More informationAt initial diagnosis, patients with
Malignant Lymphomas Decision Making and Problem Solving Current treatment and immunotherapy of Hodgkin s lymphoma Beate Klimm Roland Schnell Volker Diehl Andreas Engert The treatment of Hodgkin s lymphoma
More informationLymphology 28 (1995) 73-77
73 Lymphology 28 (1995) 73-77 Lymphological Laboratory (PH), Department of Gynecology, University of Tiibingen, Germany and Fifth Department of Internal Medicine (EZ), Silesian Medical Academy, Poland
More informationThe Present: Optimizing Therapy Too Much or Too Little?
CLINICAL ADVANCES IN HODGKIN LYMPHOMA The Present: Optimizing Therapy Too Much or Too Little? Nancy L. Bartlett 1 1 Siteman Cancer Center, Washington University, St. Louis, MO Despite the use of less toxic
More informationRT in Hodgkin Lymphoma
RT in Hodgkin Lymphoma Lesser is better? Philip Poortmans, M.D. Ph.D. Radiation oncologist Tilburg, The Netherlands Radiation dose in Hodgkin Lymphoma Introduction Current evidence Guidelines 1.0 Early
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress WHAT IS THE BEST PROTOCOL FOR CANINE LYMPHOMA? Antony S. Moore, M.V.Sc., Dipl. A.C.V.I.M. (Oncology) Veterinary
More informationHodgkin's Disease Published on Diagnostic Imaging (http://www.diagnosticimaging.com)
Hodgkin's Disease April 0, 2005 By Gary P. Engstrom, MD [], David B. Sanford, MD [2], and Fredrick B. Hagemeister, MD [3] Although there have been many advances in the treatment of Hodgkin's disease, diagnosis
More informationABVD or BEACOPP for advanced Hodgkin lymphoma. Not to BEACOPP. Massimo Federico University of Modena and Reggio Emilia Italy
ABVD or BEACOPP for advanced Hodgkin lymphoma Not to BEACOPP Massimo Federico University of Modena and Reggio Emilia Italy What is the best Induction Therapy for Advanced Hodgkin Lymphoma? How to treat
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationRadiation therapy (RT) has conventionally
Haematologica 2000; 85:1032-1039 original paper Malignant Lymphomas Treatment of early-stage Hodgkin s disease with four cycles of ABVD followed by adjuvant radiotherapy: analysis of efficacy and long-term
More informationEarly and intermediate stage Hodgkin's lymphoma - report from the Swedish National Care Programme.
Early and intermediate stage Hodgkin's lymphoma - report from the Swedish National Care Programme. Molin, Daniel; Enblad, Gunilla; Gustavsson, Anita; Ekman, Tor; Erlanson, Martin; Haapaniemi, Eva; Glimelius,
More informationReview. Management of early stage Hodgkin's disease: The role of radiation therapy and/or chemotherapy. P. M. Mauch
Annals of Oncology 7 (SuppL 4): S79-S84, 1996. O 1996 Kluwer Academic Publishers. Printed in the Netherlands. Review Management of early stage Hodgkin's disease: The role of radiation therapy and/or chemotherapy
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationNew developments in staging and follow-up of patients with Hodgkin s lymphoma
REVIEW New developments in staging and follow-up of patients with Hodgkin s lymphoma D.J van Spronsen 1*, G.J. Veldhuis 2 1 Department of Medical Oncology 550, University Medical Centre St Radboud, PO
More informationTreating Hodgkin Lymphoma
Treating Hodgkin Lymphoma General treatment information If you (or your child) has been diagnosed with Hodgkin lymphoma, the cancer care team will discuss treatment options with you. It s important to
More informationHodgkin's Lymphoma. Symptoms. Types
Hodgkin's lymphoma (Hodgkin's disease) usually develops in the lymphatic system, a part of the body's immune system. This system carries disease-fighting white blood cells throughout the body. Lymph tissue
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationProfessor Maurice Tubiana
Professor Maurice Tubiana The French way of life Dr. Odile Schweisguth Pediatric Radiation Oncology Daniele Sarrazin Pediatric Radiation Oncology Stanford Visitors from France A Massiot 1958 Courbevoie
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationDr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA???
Dr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA??? History of Radiotherapy 1895 Rontgen describes X-rays 1896 Becquerel radioactivity 1905 Radiation is used to treat tumours
More informationElderly Patients with Hodgkin s Lymphoma: FIL experience. Massimo Federico University of Modena and Reggio Emilia
Elderly Patients with Hodgkin s Lymphoma: FIL experience Massimo Federico University of Modena and Reggio Emilia RESULTS OF VbMp CHEMOTHERAPY REGIMEN IN ELDERLY PATIENTS WITH HODGKIN DISEASE: THE GISL
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationHodgkin Lymphoma: Umberto Ricardi
Hodgkin Lymphoma: Radiation Volumes Umberto Ricardi Università di Torino The changing role of RT in the cure of HL From Maximal use as a single agent To Combination of chemotherapy and full dose-full volume
More informationEvidence-Based Focused Review
Evidence-Based Focused Review Evidence-based focused review of the role of radiation therapy in the treatment of early-stage Hodgkin lymphoma Michael Crump, 1 Jordan Herst, 2 Fulvia Baldassarre, 3 Jonathan
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationRole of modern radiation therapy in early stage Hodgkin s lymphoma: A young radiation oncologists perspective
reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 246 250 Available online at www.sciencedirect.com jo u r n al hom epage: http://www.elsevier.com/locate/rpor Review Role of modern radiation
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationRituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial Bradley C. Ekstrand, Jennifer B. Lucas, Steven M. Horwitz, Zhen
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationHodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP. Volker Diehl for the German Hodgkin Study Group
Hodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP Volker Diehl for the German Hodgkin Study Group Moscow 25.October 2007 HD8 trial design CS IA, IB, IIA,B with risk factors Random
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Hodgkin s Lymphoma in Children Aged 6 Years Or Below- Long Term Follow Up Results Giri G V
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationClinical Characteristics and Treatment Response of Hodgkin s Lymphoma in Taiwan
ORIGINAL ARTICLE Clinical Characteristics and Treatment Response of Hodgkin s Lymphoma in Taiwan Shang-Ju Wu, 1 Chien-Yuan Chen, 1 Ih-Jen Su, 2 Jih-Luh Tang, 1 Wen-Chen Chou, 1,3 Bo-Sheng Ko, 1 Sheng-Yi
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationChlVPP IS AS EFFECTIVE AS ALTERNATING ChlVPP/ABOD IN ADVANCED STAGE HODGKIN S DISEASE
ChlVPP IS AS EFFECTIVE AS ALTERNATING ChlVPP/ABOD IN ADVANCED STAGE HODGKIN S DISEASE HARALD HOLTE, OLAV MELLA, ERIK WIST, RAGNAR TELHAUG, EINAR HANNISDAL and ARNE Foss ABRAHAMSEN Acta Oncol Downloaded
More informationCHOP CHEMOTHERAPY OF INTERMEDIATE AND HIGH-GRADE NON-HODGKIN S LYMPHOMA
Aria Oncologicu Vol., No. 8, pp. 95-99, 1994 CHOP CHEMOTHERAPY OF INTERMEDIATE AND HIGH-GRADE NON-HODGKIN S LYMPHOMA MARTA LLANOS, JOSEP TABERNERO, JOAN BRUNET, MARGARITAMENEDO, CINTA PALLARES, LUIS DE
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationLow acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkins disease
Ann Hematol (2004) 83:176 182 DOI 10.1007/s00277-003-0727-9 ORIGINAL ARTICLE O. Brosteanu D. Hasenclever M. Loeffler V. Diehl German Hodgkin s Lymphoma Study Group Low acute hematological toxicity during
More informationHodgkin Lymphoma Review of characteristics and treatment of elderly patients
Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Boris Böll M.D. German Hodgkin Study Group (GHSG) University Hospital Cologne OS of HL patients in all stages 1960-1967 Courtesy
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationAlexander Fosså, M.D. PhD.
Alexander Fosså, M.D. PhD. Current position: Senior Consultant, Department of Medical Oncology Oslo University Hospital Focus of work: - Malignant lymphoma - Chemotherapy, immunotherapy, radiotherapy -
More informationABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS
ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy
More informationHodgkin Lymphoma-Stage III and IV EVIDENCE TABLE
. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008. 2. Lister TA, Crowther D, Sutcliffe SB, et al. Report
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationONCOLOGY BOARD REVIEW MANUAL. Table of Contents
ONCOLOGY BOARD REVIEW MANUAL STATEMENT OF EDITORIAL PURPOSE The Hospital Physician Oncology Board Review Manual is a study guide for fellows and practicing physicians preparing for board examinations in
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationLung hilar Ga-67 uptake in patients with lymphoma following chemotherapy
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 18, No. 5, 391 397, 2004 Lung hilar Ga-67 uptake in patients with lymphoma following chemotherapy Emel Ceylan GUNAY,* Bilge Volkan SALANCI,* Ibrahim BARISTA**
More informationIntroduction. Acta Medica Mediterranea, 2015, 31: 1195
Acta Medica Mediterranea, 2015, 31: 1195 CLINICAL CHARACTERISTICS, POST-TREATMENT ASSESSMENT AND PROGNOSTIC FACTORS AFFECTING PATIENT SURVIVAL OF PATIENTS AT 65 YEARS OF AGE OR OLDER WITH HODGKIN LYMPHOMA:
More informationNavigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed
More information